 It is suggested that suppressor mutations in the "ETV6" gene may be a contributing factor in the development ant/or progression of this leukemia type.Patients developing hematological malignancies secondary to the "ETV6" gene fusion to receptor tyrosine kinases and non-receptor tyrosine kinases may be sensitive to therapy with tyrosine kinase inhibitors.For example, patients with clonal eosinophilias due to "PDGFRA" or "PDGFRB" fusion genes experience long-term, complete remission when treated with are highly sensitive tyrosine kinase inhibitor, gleevec.